Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
Retrieved on:
Tuesday, August 16, 2022
Association, Multimedia, International Association of Research Institutes in the History of Art, Molecular biophysics, Section, Valganciclovir, Porcine circovirus associated disease, Gene expression, American Cancer Society, Cancer, International Symposium on Endovascular Therapy, Yale School of Medicine, PLOS Pathogens, Research, Knowledge, Epstein–Barr virus, Department, Director, Infection, DNA, Therapy, Cell proliferation, Prognosis, Journal, SAN, Associate, Society, Drug development, Cytokine, Virus, International Association, National Cancer Institute, Publication, EBV, Yale University, Nasdaq, Biochemistry, National, Organization, Vaccine, Pharmaceutical industry, Microbiology, Pathology, Virology
SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.
Key Points:
- SAN DIEGO, Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.
- The International Association for Research on Epstein-Barr Virus and Associated Diseases is a 35-year-old non-profit organization.
- The association organizes the International Symposium on EBV research; a convention that encourages cooperative activities between institutions, organizations and societies that have interests in common relating to basic and applied research on EBV and associated diseases.
- I look forward to contributing to further advancements in the understanding of EBV, and the treatment of EBV-associated diseases."